These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 15661225)
1. 17-Allyamino-17-demethoxygeldanamycin and 17-NN-dimethyl ethylene diamine-geldanamycin have cytotoxic activity against multiple gynecologic cancer cell types. Gossett DR; Bradley MS; Jin X; Lin J Gynecol Oncol; 2005 Feb; 96(2):381-8. PubMed ID: 15661225 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo. Schwock J; Pham NA; Cao MP; Hedley DW Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866 [TBL] [Abstract][Full Text] [Related]
4. Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Smith V; Sausville EA; Camalier RF; Fiebig HH; Burger AM Cancer Chemother Pharmacol; 2005 Aug; 56(2):126-37. PubMed ID: 15841378 [TBL] [Abstract][Full Text] [Related]
5. Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to Taxol. Solit DB; Basso AD; Olshen AB; Scher HI; Rosen N Cancer Res; 2003 May; 63(9):2139-44. PubMed ID: 12727831 [TBL] [Abstract][Full Text] [Related]
6. Enhanced tumor cell radiosensitivity and abrogation of G2 and S phase arrest by the Hsp90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Bull EE; Dote H; Brady KJ; Burgan WE; Carter DJ; Cerra MA; Oswald KA; Hollingshead MG; Camphausen K; Tofilon PJ Clin Cancer Res; 2004 Dec; 10(23):8077-84. PubMed ID: 15585643 [TBL] [Abstract][Full Text] [Related]
7. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines. Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615 [TBL] [Abstract][Full Text] [Related]
8. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212 [TBL] [Abstract][Full Text] [Related]
9. [Heat shock protein 90: novel target for cancer therapy]. Chen Y; Ding J Ai Zheng; 2004 Aug; 23(8):968-74. PubMed ID: 15301726 [TBL] [Abstract][Full Text] [Related]
10. Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Bisht KS; Bradbury CM; Mattson D; Kaushal A; Sowers A; Markovina S; Ortiz KL; Sieck LK; Isaacs JS; Brechbiel MW; Mitchell JB; Neckers LM; Gius D Cancer Res; 2003 Dec; 63(24):8984-95. PubMed ID: 14695217 [TBL] [Abstract][Full Text] [Related]
11. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Yin X; Zhang H; Burrows F; Zhang L; Shores CG Clin Cancer Res; 2005 May; 11(10):3889-96. PubMed ID: 15897590 [TBL] [Abstract][Full Text] [Related]
12. Hormone-refractory breast cancer remains sensitive to the antitumor activity of heat shock protein 90 inhibitors. Beliakoff J; Bagatell R; Paine-Murrieta G; Taylor CW; Lykkesfeldt AE; Whitesell L Clin Cancer Res; 2003 Oct; 9(13):4961-71. PubMed ID: 14581371 [TBL] [Abstract][Full Text] [Related]
13. Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation. Yun BG; Matts RL Exp Cell Res; 2005 Jul; 307(1):212-23. PubMed ID: 15922741 [TBL] [Abstract][Full Text] [Related]
14. Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Hostein I; Robertson D; DiStefano F; Workman P; Clarke PA Cancer Res; 2001 May; 61(10):4003-9. PubMed ID: 11358818 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic relationships for the heat shock protein 90 molecular chaperone inhibitor 17-allylamino, 17-demethoxygeldanamycin in human ovarian cancer xenograft models. Banerji U; Walton M; Raynaud F; Grimshaw R; Kelland L; Valenti M; Judson I; Workman P Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7023-32. PubMed ID: 16203796 [TBL] [Abstract][Full Text] [Related]
16. 17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels. Braga-Basaria M; Hardy E; Gottfried R; Burman KD; Saji M; Ringel MD J Clin Endocrinol Metab; 2004 Jun; 89(6):2982-8. PubMed ID: 15181088 [TBL] [Abstract][Full Text] [Related]
17. Degradation of HER2 by ansamycins induces growth arrest and apoptosis in cells with HER2 overexpression via a HER3, phosphatidylinositol 3'-kinase-AKT-dependent pathway. Münster PN; Marchion DC; Basso AD; Rosen N Cancer Res; 2002 Jun; 62(11):3132-7. PubMed ID: 12036925 [TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90. Ge J; Normant E; Porter JR; Ali JA; Dembski MS; Gao Y; Georges AT; Grenier L; Pak RH; Patterson J; Sydor JR; Tibbitts TT; Tong JK; Adams J; Palombella VJ J Med Chem; 2006 Jul; 49(15):4606-15. PubMed ID: 16854066 [TBL] [Abstract][Full Text] [Related]
19. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Ibrahim NO; Hahn T; Franke C; Stiehl DP; Wirthner R; Wenger RH; Katschinski DM Cancer Res; 2005 Dec; 65(23):11094-100. PubMed ID: 16322259 [TBL] [Abstract][Full Text] [Related]
20. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Nimmanapalli R; O'Bryan E; Bhalla K Cancer Res; 2001 Mar; 61(5):1799-804. PubMed ID: 11280726 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]